CAR T cells’ variable regions are directed against a tumor target of interest, most often CD19 for B-lineage lymphomas and leukemias and more recently B cell maturation antigen (BCMA) for multiple myeloma [9,10,11]. Here, TNFRSF17 is linked to plasma cell myeloma.